We are live on ! Find out more

EUDA Health Holdings

EUDA

Market cap $49.2M

16.42 USD

-0.91

5.25%

At close Updated Sep 24, 4:00 PM EDT

1 day

-5.25%

5 days

-4.53%

1 month

6.62%

3 months

13.24%

6 months

79.85%

Year to date

-66.63%

1 year

-55.62%

5 years

-91.49%

10 years

-91.49%

About: EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.

Employees: 123

Real Estate Real Estate Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore

SINGAPORE, AUGUST, Aug. 26, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based distributor of third-party wellness and non-invasive healthcare products and services in Singapore, Malaysia and China, as well as property management services in Singapore, today announced that its subsidiary, Melana International Pte. Ltd. (“Melana”), was recognised as one of the winners of the SME100 Awards 2026 Singapore, organised by Business Media International.

EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

SINGAPORE, July 30, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today provided important additional details of the integrated cell therapy program to be pursued under its recently announced non-binding Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd (“GO POSB”) and Shenzhen Innovation Immunotechnology Co., Ltd. (“SIIT”).

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

SINGAPORE, July 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today announced that it has signed a Memorandum of Understanding (“MOU”) with GO POSB Organoids Pte Ltd (“GO POSB”) and Shenzhen Innovation Immunotechnology Co., Ltd. (“SIIT”) to establish a tri-party collaboration with next-generation therapies derived from induced pluripotent stem cells (“iPSC”).

EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced it is expanding the Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask (“Regenixé Mask”), a beauty product developed by Chemokine Pte Ltd (“Chemokine”).

EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

Singapore, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities (“MVLS”) of $35 million over the last 32 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2).

EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

EUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

SINGAPORE, April 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced that Shenzhen Inno Immune Co., Ltd. (“Shenzhen Inno”), a developer of cellular therapies in China, has received official approval under the 2025 Shenzhen Key Industry R&D Program.

EUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

EUDA Announces Reverse Stock Split of its Ordinary Shares

SINGAPORE, March 19, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it will implement a reverse stock split of its ordinary shares at a ratio of 1-for-20 (the “Reverse Stock Split”). The Reverse Stock Split was approved by the Company's Board of Directors in accordance with British Virgin Islands law. The Reverse Stock Split will take effect at market open on March 23, 2026, and the ordinary shares will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol “EUDA” and will continue to trade under that symbol. The new CUSIP number for EUDA's ordinary shares following the Reverse Stock Split will be G3142E147.

EUDA Announces Reverse Stock Split of its Ordinary Shares

EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant

SINGAPORE, March 04, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has repurchased and cancelled in full the warrant previously issued to Streeterville Capital, LLC.

EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant

EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform

SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that its wholly owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutics and customised medicines for a wide range of diseases in China.

EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform

EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement

SINGAPORE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has entered into an amendment (the “Warrant Amendment”) to its previously disclosed warrant agreement with Streeterville Capital, LLC (“Streeterville Capital”).

EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement

See News Rankings

Price charts implemented using Lightweight Charts™